Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study.

Journal of the European Academy of Dermatology and Venereology : JEADV
A T TouhoucheM Tauber

Abstract

Dupilumab is approved for use in moderate-to-severe atopic dermatitis (AD) and as an add-on maintenance treatment in patients suffering from severe asthma with type 2 inflammation. Ocular adverse events (OAEs) have been reported with dupilumab almost exclusively in patients treated for AD. The objectives of this study were to describe the incidence and nature of dupilumab-induced OAEs and to assess the potential predisposing factors. We conducted a prospective, single-centre, real-life study in adult AD patients treated with dupilumab, who were systematically examined by an ophthalmologist before and during treatment. Forty-six patients were included prospectively with a median age of 41.1 years and a median initial SCOring Atopic Dermatitis of 46.0 (IQR: 34.5-55.5). OAEs concerned 34.8% of patients and were mostly of mild to moderate severity. Two patients had to discontinue treatment due to OAE. The majority of patients developed or aggravated dry eye disease, with superficial punctate keratitis (SPK). Six patients developed conjunctivitis. Dupilumab-induced OAEs were associated with the following pre-existing parameters: dry eye disease with SPK (Odds ratio (OR); 6.3 [95% confidence interval (CI): 1.3-31.6]), eyelid eczema (...Continue Reading

References

Jan 1, 1976·ORL; Journal for Oto-rhino-laryngology and Its Related Specialties·J Gontier, U Fisch
May 1, 1994·Clinical and Experimental Dermatology·A Y Finlay, G K Khan
Jan 1, 1993·Dermatology : International Journal for Clinical and Investigative Dermatology
Sep 18, 2007·Current Opinion in Allergy and Clinical Immunology·Andrea LeonardiLaura Motterle
Aug 20, 2010·Current Opinion in Allergy and Clinical Immunology·Stefano GuglielmettiVirginia Calder
May 22, 2013·The New England Journal of Medicine·Sally WenzelGianluca Pirozzi
Sep 17, 2013·The Journal of Allergy and Clinical Immunology·Jochen SchmittUNKNOWN Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative
Dec 18, 2013·Journal of the American Academy of Dermatology·Joseph J ChenStephen C Pflugfelder
Jul 10, 2014·The New England Journal of Medicine·Lisa A BeckAllen R Radin
Jul 2, 2015·Investigative Ophthalmology & Visual Science·Johanna Tukler HenrikssonStephen C Pflugfelder
Dec 22, 2015·Journal of the American Academy of Dermatology·Masaki FutamuraEric L Simpson
Feb 3, 2016·JAMA : the Journal of the American Medical Association·Claus BachertE Rand Sutherland
Sep 25, 2016·The Journal of Allergy and Clinical Immunology·Joseph D SpahnStanley J Szefler
Oct 4, 2016·The New England Journal of Medicine·Eric L SimpsonUNKNOWN SOLO 1 and SOLO 2 Investigators
Mar 16, 2017·The New England Journal of Medicine·Eric L SimpsonMarius Ardeleanu
Mar 17, 2017·The New England Journal of Medicine·Maurizio MenniniAlessandro Fiocchi
Dec 21, 2017·American Journal of Ophthalmology Case Reports·Alexander C BarnesJulian D Perry
Feb 13, 2018·The Journal of Allergy and Clinical Immunology. in Practice·Andreas WollenbergMarjolein de Bruin-Weller
May 22, 2018·The New England Journal of Medicine·Mario CastroAriel Teper
May 22, 2018·The New England Journal of Medicine·Klaus F RabeAriel Teper
Jan 1, 2019·The British Journal of Dermatology·D S BakkerM S de Bruin-Weller
Jan 18, 2019·Acta Dermato-venereologica·Lina U IvertMaria Bradley
Feb 6, 2019·The Journal of Allergy and Clinical Immunology. in Practice·Manuel Jorge RialJoaquín Sastre
Feb 6, 2019·Allergology International : Official Journal of the Japanese Society of Allergology·Ken FukudaAtsuki Fukushima
Mar 3, 2019·Journal of the American Academy of Dermatology·Sarah FaizUNKNOWN Groupe de Recherche sur l'Eczéma aTopique (GREAT), France
Mar 10, 2019·The British Journal of Dermatology·B AkinladeA Wollenberg
Apr 18, 2019·JAMA Dermatology·Alison D TreisterPeter A Lio
Jun 24, 2019·Ophthalmology and Therapy·Adrien MaudinetThi Ha Chau Tran
Jul 28, 2019·The Journal of Allergy and Clinical Immunology. in Practice·Jorge F MasperoAriel Teper
Sep 16, 2019·The Journal of Allergy and Clinical Immunology. in Practice·Jonathan CorrenAriel Teper

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.